دورية أكاديمية
In Vitro Study of the Multimodal Effect of Na + /K + ATPase Blocker Ouabain on the Tumor Microenvironment and Malignant Cells.
العنوان: | In Vitro Study of the Multimodal Effect of Na + /K + ATPase Blocker Ouabain on the Tumor Microenvironment and Malignant Cells. |
---|---|
المؤلفون: | Harich OO; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania., Gavriliuc OI; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania., Ordodi VL; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.; Faculty of Industrial Chemistry and Environmental Engineering, 'Politehnica' University Timisoara, No 2 Victoriei Square, 300006 Timisoara, Romania., Tirziu A; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania., Paunescu V; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.; Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen, Clinical Emergency County Hospital 'Pius Brinzeu' Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania., Panaitescu C; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.; Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen, Clinical Emergency County Hospital 'Pius Brinzeu' Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania., Bojin MF; Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, 'Victor Babes' University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.; Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen, Clinical Emergency County Hospital 'Pius Brinzeu' Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania. |
المصدر: | Biomedicines [Biomedicines] 2023 Aug 05; Vol. 11 (8). Date of Electronic Publication: 2023 Aug 05. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, [2013]- |
مستخلص: | Na + /K + ATPase is a protein involved in the active transport of ions across the cellular membrane. Ouabain is a cardiotonic glycoside that, by inhibiting the Na + /K + pump, interferes with cell processes mediated directly by the pump, but also indirectly influences other cellular processes such as cell cycle and proliferation, growth, cell differentiation, angiogenesis, migration, adhesion, and invasion. We used the SK-BR-3 breast cancer cell line, mesenchymal stem cells (MSCs), and tumor-associated fibroblasts (TAFs) in vitro to determine the effects of ouabain exposure on these cellular types. The results showed a multi-level effect of ouabain mainly on tumor cells, in a dose-dependent manner, while the TAFs and their normal counterparts were not significantly influenced. Following exposure to ouabain, the SK-BR-3 cells changed their morphologic appearance, decreased the expression of immunophenotypic markers (CD29, Her2, VEGF), the proliferation rate was significantly decreased (Ki67 index), the cells were blocked in the G |
References: | Am J Physiol Cell Physiol. 2012 May 1;302(9):C1271-81. (PMID: 22277755) Oxid Med Cell Longev. 2016;2016:4350965. (PMID: 26998193) PLoS One. 2018 Mar 28;13(3):e0193779. (PMID: 29590154) FASEB J. 2019 Sep;33(9):10193-10206. (PMID: 31199885) Br J Cancer. 2012 May 22;106(11):1807-15. (PMID: 22531632) Sci Transl Med. 2012 Jul 18;4(143):143ra99. (PMID: 22814852) Front Oncol. 2021 Jun 30;11:684316. (PMID: 34277430) Cold Spring Harb Perspect Biol. 2011 Mar 01;3(3):. (PMID: 21421924) Front Physiol. 2017 Nov 10;8:895. (PMID: 29176951) Oncol Lett. 2017 Dec;14(6):6678-6684. (PMID: 29163695) Int J Mol Sci. 2018 Jun 04;19(6):. (PMID: 29867020) Curr Top Membr. 2019;83:315-351. (PMID: 31196608) Oncol Lett. 2013 Aug;6(2):475-479. (PMID: 24137350) Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198. (PMID: 25818339) J Oral Sci. 2019 Nov 27;61(4):498-503. (PMID: 31548455) Antioxid Redox Signal. 2014 Jul 10;21(2):251-9. (PMID: 24180216) Acta Pharmacol Sin. 2020 Jan;41(1):110-118. (PMID: 31515527) Sci Rep. 2020 Apr 7;10(1):6006. (PMID: 32265464) Mol Med Rep. 2018 Apr;17(4):5595-5600. (PMID: 29436645) Ann N Y Acad Sci. 2003 Apr;986:497-503. (PMID: 12763870) Cell Signal. 2018 Nov;51:222-232. (PMID: 30102978) PLoS One. 2013 Jul 10;8(7):e68623. (PMID: 23874694) J Membr Biol. 2014 Jan;247(1):23-33. (PMID: 24186357) Pharm Pat Anal. 2012 Mar;1(1):91-106. (PMID: 24236716) Anticancer Res. 2014 Oct;34(10):5495-502. (PMID: 25275046) Toxicon. 2019 Feb;158:63-68. (PMID: 30529380) Biomolecules. 2021 Aug 25;11(9):. (PMID: 34572488) Int J Mol Sci. 2019 Dec 25;21(1):. (PMID: 31881671) Med Sci Monit. 2019 Dec 11;25:9426-9434. (PMID: 31822650) Front Med. 2018 Aug;12(4):412-425. (PMID: 30054853) Pathol Res Pract. 2020 Jan;216(1):152729. (PMID: 31735322) Cell. 2012 Mar 30;149(1):22-35. (PMID: 22464321) J Cell Mol Med. 2011 Mar;15(3):635-46. (PMID: 20184663) Neuroimmunomodulation. 2019;26(4):188-197. (PMID: 31412342) Front Physiol. 2017 Jun 06;8:371. (PMID: 28634454) Pharmacol Res Perspect. 2019 Jul 19;7(4):e00505. (PMID: 31360524) Am J Physiol Cell Physiol. 2016 Apr 1;310(7):C491-5. (PMID: 26791490) Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834) Mol Interv. 2003 May;3(3):157-68. (PMID: 14993422) Oncotarget. 2015 Nov 3;6(34):35522-41. (PMID: 26431493) J Biol Chem. 2013 Feb 22;288(8):5803-14. (PMID: 23288841) Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3792-3804. (PMID: 30251696) Environ Toxicol. 2019 Dec;34(12):1329-1339. (PMID: 31436044) Int J Biochem Cell Biol. 2004 Mar;36(3):379-85. (PMID: 14687915) |
معلومات مُعتمدة: | POC 92/09/09/2016 Ministry of Investments and European Projects Romania |
فهرسة مساهمة: | Keywords: MSC; Na+/K+ ATPase; SK-BR-3 tumor cells; TAFs; molecular target; ouabain |
تواريخ الأحداث: | Date Created: 20230826 Latest Revision: 20230828 |
رمز التحديث: | 20230828 |
مُعرف محوري في PubMed: | PMC10452365 |
DOI: | 10.3390/biomedicines11082205 |
PMID: | 37626702 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2227-9059 |
---|---|
DOI: | 10.3390/biomedicines11082205 |